Key Points
- Medpace VP Susan Burwig sold 18,000 shares at an average price of $605, totaling $10,890,000, cutting her stake by 27.48% to 47,500 shares.
- Medpace beat quarterly expectations with $3.86 EPS and revenue up 23.7%, set FY2025 guidance of 14.600–14.860 EPS, while analysts' consensus is a "Hold" with a $475.90 target.
Medpace Holdings, Inc. (NASDAQ:MEDP - Get Free Report) VP Susan Burwig sold 18,000 shares of the business's stock in a transaction dated Tuesday, November 11th. The shares were sold at an average price of $605.00, for a total value of $10,890,000.00. Following the sale, the vice president directly owned 47,500 shares of the company's stock, valued at $28,737,500. This represents a 27.48% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.
Medpace Stock Down 0.9%
NASDAQ MEDP opened at $597.60 on Thursday. Medpace Holdings, Inc. has a 52 week low of $250.05 and a 52 week high of $625.00. The company has a market capitalization of $16.83 billion, a P/E ratio of 41.79, a price-to-earnings-growth ratio of 2.67 and a beta of 1.42. The stock's 50-day moving average price is $535.14 and its 200-day moving average price is $419.62.
Medpace (NASDAQ:MEDP - Get Free Report) last announced its quarterly earnings data on Wednesday, October 22nd. The company reported $3.86 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $3.50 by $0.36. The company had revenue of $659.90 million during the quarter, compared to the consensus estimate of $640.49 million. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm's revenue was up 23.7% on a year-over-year basis. During the same period in the previous year, the company posted $3.01 EPS. Medpace has set its FY 2025 guidance at 14.600-14.860 EPS. Research analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.
Analysts Set New Price Targets
A number of analysts have recently issued reports on MEDP shares. Cowen reissued a "sell" rating on shares of Medpace in a research note on Friday, October 24th. Weiss Ratings reiterated a "buy (b)" rating on shares of Medpace in a research note on Friday, October 31st. Deutsche Bank Aktiengesellschaft raised their price target on Medpace from $270.00 to $430.00 and gave the company a "hold" rating in a report on Wednesday, July 23rd. Mizuho upped their price objective on Medpace from $575.00 to $655.00 and gave the stock an "outperform" rating in a research note on Friday, October 24th. Finally, Wall Street Zen upgraded Medpace from a "hold" rating to a "buy" rating in a research report on Saturday, October 25th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, nine have given a Hold rating and four have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $475.90.
Read Our Latest Report on Medpace
Institutional Trading of Medpace
Several hedge funds have recently bought and sold shares of MEDP. Quent Capital LLC purchased a new position in shares of Medpace during the third quarter valued at about $25,000. Optiver Holding B.V. purchased a new stake in shares of Medpace in the third quarter worth about $27,000. Geneos Wealth Management Inc. lifted its position in shares of Medpace by 64.9% in the first quarter. Geneos Wealth Management Inc. now owns 94 shares of the company's stock worth $29,000 after buying an additional 37 shares in the last quarter. Brooklyn Investment Group boosted its stake in Medpace by 244.8% during the first quarter. Brooklyn Investment Group now owns 100 shares of the company's stock valued at $30,000 after buying an additional 71 shares during the last quarter. Finally, Whittier Trust Co. boosted its stake in Medpace by 47.3% during the first quarter. Whittier Trust Co. now owns 109 shares of the company's stock valued at $33,000 after buying an additional 35 shares during the last quarter. Hedge funds and other institutional investors own 77.98% of the company's stock.
About Medpace
(
Get Free Report)
Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
